Date:
May 16, 2014
Source:
University of Southampton
Summary:
Doctors and scientists have completed their first hip surgery with a 3D-printed implant and bone stem cell graft. The 3D printed hip, made from titanium, was designed using the patient's CT scan and CAD CAM (computer aided design and computer aided manufacturing) technology, meaning it was designed to the patient's exact specifications and measurements. The implant will provide a new socket for the ball of the femur bone to enter. Behind the implant and between the pelvis, doctors have inserted a graft containing bone stem cells.
Doctors and scientists in Southampton have completed their first hip surgery with a 3D printed implant and bone stem cell graft.
The 3D printed hip, made from titanium, was designed using the patient's CT scan and CAD CAM (computer aided design and computer aided manufacturing) technology, meaning it was designed to the patient's exact specifications and measurements.
The implant will provide a new socket for the ball of the femur bone to enter. Behind the implant and between the pelvis, doctors have inserted a graft containing bone stem cells.
(http://www.sciencedaily.com/releases/2014/05/140516203334.htm)
Procedure delivers stem cells to the heart to repair damaged muscle and arteries
December 2, 2013
Patel started investigating cell and gene-based therapies for the treatment of heart disease 12 years ago, but only recently received FDA approval to try the therapy on Lively, who was the first of several patients anxious to receive the treatment.
More than 6 million people are currently living with heart failure. As the condition progresses, patients’ options are usually limited to a heart transplant or assist devices, such as an artificial heart. Patel wanted to find a way to intervene in the progression of heart failure before a patient advanced to the point of needing a heart transplant or device.
(http://www.kurzweilai.net/first-use-of-retrograde-gene-therapy-on-a-human-heart)
Wed, 08/14/2013 - 12:00pm
The first clinical trial of revolutionary stem cells that won a Nobel Prize for their developer has been greenlit.
The cells, called induced pluripotent stem (iPS) Cells, will be morphed into retinal cells, then given to six patients with a major cause of blindness: age-related macular degeneration (AMD).
The trial, approved by Japan Health Minister Norihisa Tamura, will be led next summer by Masayo Takahashi. She is a retina regeneration expert, and a colleague of the man who first developed iPS cells: Shinya Yamanaka.
The trial epitomizes, to many, Japan’s determination to dominate the iPS cell field, an ambition that kicked into high gear when Yamanaka shared the Nobel Prize for Physiology or Medicine last October for his iPS cell work.
“If things continue this way, this will be the first in-clinic study in iPS cell technology,” says Doug Sipp of the Riken Center for Developmental Biology (CDB). The CDB, Takahashi’s institute, will co-run the trial with Kobe’s Institute for Biomedical Research and Innovation. "It's exciting."
Read the whole article at Bio Science Technology